Adage Capital Partners’s Indaptus Therapeutics INDP Stock Holding History

Adage Capital Partners’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-652	Closed	-$414K	–	788
2020 Q2	$414K	Hold	652	–	–	﹤0.01%	718
2020 Q1	$288K	Hold	652	–	–	﹤0.01%	712
2019 Q4	$730K	Hold	652	–	–	﹤0.01%	685
2019 Q3	$1.06M	Sell	652 -107	-14%	-$318K	﹤0.01%	681
2019 Q2	$7.38M	Hold	759	–	–	0.02%	564
2019 Q1	$12.5M	Hold	759	–	–	0.03%	485
2018 Q4	$12.8M	Sell	759 -145	-16%	-$1.98M	0.04%	447
2018 Q3	$11.4M	Hold	904	–	–	0.03%	528
2018 Q2	$8.91M	Buy	904 +134	+17%	+$1.49M	0.02%	582
2018 Q1	$10.9M	Hold	770	–	–	0.03%	539
2017 Q4	$8.88M	Hold	770	–	–	0.02%	581
2017 Q3	$15.4M	Buy	+770	New	+$11.1M	0.04%	476

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Adage Capital Partners's INDP Position: Q3 2020 in Review

Adage Capital Partners sold out of Indaptus Therapeutics (INDP) in Q3 2020, closing a stake of 652 shares — an estimated $414K sold.

Adage Capital Partners first reported a position in INDP in Q3 2017 and held it in 12 quarters. The position peaked at $15.4M in Q3 2017. 24 funds tracked by Wall St. Rank hold INDP as of Q3 2020.

Adage Capital Partners reported no remaining Indaptus Therapeutics position as of Q3 2020 after selling out during the quarter.
Adage Capital Partners sold 652 Indaptus Therapeutics shares in Q3 2020, an estimated $414K.
Adage Capital Partners first reported a position in Indaptus Therapeutics in Q3 2017 and held it in 12 quarters.
Adage Capital Partners's Indaptus Therapeutics position peaked at $15.4M in Q3 2017.
24 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2020.

Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.